A double-blind, randomized, placebo-controlled study of the efficacy, safety and tolerability of 8-week treatment of Rozerem [ramelteon] 8mg (QHS) in sleep-disturbed, community-dwelling, mild to moderately severe Alzheimer's disease subjects

Trial Profile

A double-blind, randomized, placebo-controlled study of the efficacy, safety and tolerability of 8-week treatment of Rozerem [ramelteon] 8mg (QHS) in sleep-disturbed, community-dwelling, mild to moderately severe Alzheimer's disease subjects

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 19 Jan 2010

At a glance

  • Drugs Ramelteon (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top